

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 May 2026

The Investigating the effect of magnesium supplementation on stress and ovulation rate in infertile women with polycystic ovary syndrome

Protocol summary

Study aim

Determining the effect of magnesium supplementation on stress and ovulation rate in infertile women with polycystic ovary syndrome

Design

Clinical trial with control group, with parallel group, double-blind, randomized, www.sealedenvelope.com site was used for randomization.

Settings and conduct

All infertile women referred to the infertility center of Bent El Hoda Hospital in Bojnurd and with polycystic ovary syndrome and candidates for drug treatment. Eligible individuals will complete Newton's Infertility Stress and Demographic Questionnaires. Their height and weight are measured with a seca digital foot scale to calculate BMI. The 3-day food reminder questionnaire is given to volunteers who have a score higher than 46 on the infertility stress scale and have a BMI less than 35, in order to determine the daily intake of each person in terms of total energy, carbohydrates, magnesium, and calcium, potassium and caffeine to be determined. Participants who receive magnesium diet less than 75% of RDA are referred to receive pills and perform ultrasound to confirm polycystic ovaries on the third day of their period.

Participants/Inclusion and exclusion criteria

Infertility for more than a year Not using medicinal compounds and supplements containing magnesium. Not taking anti-anxiety and sedative drugs. Body mass index less than 35, Magnesium intake less than 75% of the recommended dietary intake

Intervention groups

Each participant is given a package containing 112 tablets (magnesium/placebo) for 8 weeks and is advised to take two tablets daily from the same day. The intervention group will take magnesium supplements twice a day in the form of magnesium oxide tablets (each tablet contains 250 mg of elemental magnesium) and the control group will take placebo tablets for 8

weeks.

Main outcome variables

Determining the rate of stress and ovulation following magnesium supplementation

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20091229002924N3**

Registration date: **2024-01-17, 1402/10/27**

Registration timing: **prospective**

Last update: **2024-01-17, 1402/10/27**

Update count: **0**

Registration date

2024-01-17, 1402/10/27

Registrant information

Name

Maryam Hassanzadeh Bashtian

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 58 3151 1206

Email address

m.h.bashtian@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-02-20, 1402/12/01

Expected recruitment end date

2024-12-05, 1403/09/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The Investigating the effect of magnesium supplementation on stress and ovulation rate in infertile women with polycystic ovary syndrome

Public title

Investigating the effect of magnesium supplementation on stress and ovulation

Purpose

Other

Inclusion/Exclusion criteria**Inclusion criteria:**

Infertility for more than a year Absence of acute and chronic diseases, Not using medicinal compounds and supplements containing magnesium. Not taking anti-anxiety and sedative drugs. Not using drugs, tobacco and alcohol. Not using relaxation techniques. Body mass index less than 35, Magnesium intake less than 75% of the recommended dietary intake

Exclusion criteria:

Pregnancy, Use of oral contraceptive pills, Occurrence of any severe stress (for example, divorce or death of a relative), Personal desire to withdraw from the study during the study, Consumption of less than 90 out of 112 magnesium supplement tablets or placebo.

Age

From **18 years** old to **45 years** old

Gender

Female

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator

Sample size

Target sample size: **108**

Randomization (investigator's opinion)

Randomized

Randomization description

Allocation of samples to intervention and placebo groups will be done using the random block method with blocks of 4 and using the website www.sealedenvelope.com. In this study, with a ratio of 1:1, the samples will be divided into intervention and placebo groups.

Blinding (investigator's opinion)

Double blinded

Blinding description

In order to hide the random allocation, sealed opaque envelopes with a random sequence will be used among the selected people to enter the two groups. Also, in the implementation of the random allocation process, the person involved in the creation of the randomization program will be separate from other researchers to reduce the possible bias of the person creating the random sequence. In order to blind the study, before the

start of the study, a set of cans containing the relevant tablets (magnesium tablets) and placebo (containing Avicel and lactose), which are completely similar to magnesium tablets in terms of shape, size and color, and manufactured by Sina Pharmaceutical Company was coded by a person other than the researcher as A (intervention group) and B (placebo group) to ensure that the researcher did not know the type of pills received in each group. Each participant is given a package containing 112 tablets (magnesium/placebo) for 8 weeks and is advised to take two tablets daily from the same day. The intervention group will take magnesium supplements twice a day in the form of magnesium oxide tablets (each tablet contains 250 mg of elemental magnesium) and the control group will take placebo tablets for 8 weeks. In order not to inform the participants of the study, magnesium supplement tablets and placebo will have similar appearance and at the first glance of an expert, they will look completely identical.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethical committee of North Khorasan University of Medical Sciences

Street address

Shahid Vaghefi street. Dolat Blvd. North Khorasan University of Medical Sciences.

City

Bojnurd

Province

North Khorasan

Postal code

74877-94149

Approval date

2023-12-27, 1402/10/06

Ethics committee reference number

IR.NKUMS.REC.1402.141

Health conditions studied**1****Description of health condition studied**

Polycystic Ovary Syndrome

ICD-10 code

E28.2

ICD-10 code description

Polycystic ovarian syndrome

Primary outcomes

1

Description

To determine the effect of magnesium supplementation on stress and ovulation rate in infertile women with polycystic ovary syndrome

Timepoint

Newton's stress questionnaire first and then 4 weeks after taking the pills and at the end of taking the pills. Vaginal ultrasound at the beginning of the study as an entry criterion and then 4 weeks after taking the pills and then between the 10th and 14th day of the trigger drug cycle.

Method of measurement

Ultrasound, Newton stress questionnaire

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: The intervention group receives magnesium supplements twice a day in the form of magnesium oxide tablets (each tablet contains 250 mg of elemental magnesium).

Category

Treatment - Drugs

2

Description

Category

empty

3

Description

Control group: The control group will take placebo pills for 8 weeks.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Infertility Department of Bent Al Hoda Hospital.
Bojnord city

Full name of responsible person

Maryam Hassanzadeh Bashtian

Street address

Dolat Blvd. Shahid Waghefi St. North Khorasan
University of Medical Sciences, second floor.

City

Bojnurd

Province

North Khorasan

Postal code

74877-94149

Phone

+98 58 3151 3001

Email

m.h.bashtian@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Bojnourd University of Medical Sciences

Full name of responsible person

Bahram Bibak

Street address

Shahriyar St. Vice Chancellor of University Research
and Technology.

City

Bojnurd

Province

North Khorasan

Postal code

9417694780

Phone

+98 58 3151 1420

Email

bibak44@googlemail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Bojnourd University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Bojnourd University of Medical Sciences

Full name of responsible person

Maryam Hassanzadeh Bashtian

Position

Faculty member

Latest degree

Ph.D.

Other areas of specialty/work

Reproductive Health

Street address

Shahriyar St. school of Nursing, Midwifery
Department.

City

Bojnurd

Province

North Khorasan

Postal code

94176-96786

Phone

+98 58 3229 7097

Email

m.h.Bashtian@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Bojnourd University of Medical Sciences

Full name of responsible person

Maryam Hassanzadeh Bashtian

Position

Faculty member

Latest degree

Ph.D.

Other areas of specialty/work

Reproductive Health

Street address

Shahriyar St. School of Medicinie & Nursing .
Midwifery Department.

City

Bojnurd

Province

North Khorasan

Postal code

94176-96786

Phone

+98 58 3229 7097

Email

m.h.bashtian@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Bojnourd University of Medical Sciences

Full name of responsible person

Maryam Hassanzadeh bashtian

Position

Faculty member

Latest degree

Ph.D.

Other areas of specialty/work

Reproductive Health

Street address

Shahriyar St. School of Medicine & Nursing. Midwifery
Department.

City

Bojnurd

Province

North Khorasan

Postal code

94176-96786

Phone

+98 58 3229 7097

Email

m.h.bashtian@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to
make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available